Quiroga, Maria
Novo Nordisk (Denmark)
2 papers on CoChat
Most cited papers
- Verified
Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
McGowan, B. M., Bruun, J. M., Capehorn, M., Pedersen, S. D., Pietiläinen, K. H., Muniraju, H. A. K., Quiroga, M., Varbo, A., & Lau, D. C. W. (2024) · The Lancet Diabetes & Endocrinology
Diabetes Treatment and ManagementPharmacology and Obesity Treatment
Cited by 176
- Verified
Once-Weekly Semaglutide 7·2 Mg in Adults with Obesity (STEP UP): A Randomised, Controlled, Phase 3b Trial
Wharton, S., Freitas, P., Hjelmesæth, J., Kabisch, M., Kandler, K., Lingvay, I., Quiroga, M., Rosenstock, J., & Garvey, W. T. (2025) · The Lancet Diabetes & Endocrinology
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 119
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free